Drug Profile
Research programme: glaucoma therapeutics - Colby Pharmaceuticals
Alternative Names: OT-411; OT-440Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Othera Pharmaceuticals
- Developer Colby Pharmaceuticals
- Class Hydroxylamines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma